|Day Low/High||0.00 / 0.00|
|52 Wk Low/High||0.00 / 0.00|
Jim Cramer shares his views on the latest moves in biotech and retail. Account, Regeneron, Burlington Stores and Five Below are among the many stocks discussed here.
Health care deals dominate the list of big mergers so far this year, while tech comes in second.
Data presented today at the American Society of Clinical Oncology Annual Meeting
Data featured in today's official press program at American Society of Clinical Oncology Annual Meeting
Jim Cramer likes the 10 early-stage drugs J&J has in its pipeline, among other reasons.
Jim Cramer reveals why his Action Alerts PLUS charitable trust portfolio is initiating coverage of Johnson & Johnson (JNJ) on Tuesday.
Trade-Ideas LLC identified Pharmacyclics (PCYC) as a new lifetime high candidate
Would Become First EMA-approved Therapy for Patients in Europe
IMBRUVICA Combination Data in Chronic Lymphocytic Leukemia to be Featured in Official ASCO Press Program
The Fed chief used some pretty frightening terms about stocks Wednesday, saying that valuations 'generally are quite high' and that there are 'potential dangers' with them.
- Note: This press release corresponds to abstract 396
Oral Presentation at the American Association of Cancer Research Annual Meeting
Mega deals from strategic players across a variety of industries pushed first-quarter deals to the highest value since 2007.
Data Published in The New England Journal of Medicine Show 91% Overall Response Rate and 95% Overall Survival
The drug companies' strengths in generics and knocks-off drugs should complement one another.
Mylan made public on Wednesday that it had made a proposal to acquire generic drugmaker Perrigo in a deal valued at $205 per share in cash and stock.
Neither of the deals announced Monday are blockbusters or particularly transformative. Both buyers have specific needs and went after small targets for large prices.
Catch up on Jim Cramer's thinking over the last week about two leadership groups that have been hammered and the spike in oil.
The shares of BioMarin are climbing after a blog reported last night that Shire is considering offering to acquire the company.
TheStreet Ratings team reiterated 3 stocks with a hold rating on Thursday
If history repeats itself, the recent weakness in biotech stocks will end with lots more buying.
Pre-clinical data to be presented in solid tumor and blood cancer models
It shouldn't be possible, but it never seems too late to get in.
It's creating investment opportunities that just shouldn't exist, Cramer says.